Markers for silent myocardial ischemia in diabetes. Are they helpful?

Diabetes and Metabolism

Volumn 31, Issue 2, 2005, Pages 205-213

  Cosson, E ^a,b   Attali, J R ^a   Valensi, P ^a  

^a UNIVERSITÉ PARIS 13   (France)

^b HÔPITAL JEAN VERDIER   (France)

Author keywords

Diabetes mellitus; Markers; Review; Silent coronary stenosis; Silent myocardial ischemia

Indexed keywords

BIOLOGICAL MARKER; CELL ADHESION MOLECULE; HOMOCYSTEINE;

AGED; AGING; ARTERY DISEASE; ARTICLE; AUTONOMIC NEUROPATHY; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DIABETES MELLITUS; DIAGNOSTIC VALUE; DISEASE MARKER; DYSLIPIDEMIA; EXERCISE; FAMILY HISTORY; FOLLOW UP; GENDER; HEALTH CARE COST; HIGH RISK POPULATION; HUMAN; HYPERTENSION; INFLAMMATION; LIFESTYLE; MALE; MICROALBUMINURIA; NUTRITION; PROTEINURIA; SCREENING TEST; SILENT MYOCARDIAL INFARCTION; SMOKING; VASCULAR ENDOTHELIUM;

EID: 14744275915     PISSN: 12623636     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1262-3636(07)70187-8     Document Type: Article

References (68)

1. Grimaldi A, Heurtier A. Epidémiologie des complications cardiovasculaires du diabétique. Diabetes Metab, 1999, 25, 12-20.
2. Cohn PF, Fox KM, Daly C. Silent myocardial ischemia. Circulation, 2003, 108, 1263-77.
3. Cohn PF. Silent myocardial ischemia. Ann Intern Med, 1988, 109, 312-7.
4. Conti CR. Silent cardiac ischemia. Curr Opin Cardiol, 2002, 17, 537-42.
5. Doubell AF. Managing the asymptomatic diabetic patient with silent myocardial ischaemia. Cardiovasc J S Afr, 2002, 13, 189-93.
6. Abenavoli T, Rubler S, Fisher VJ, Axelrod HI, Zuckerman KP. Exercise testing with myocardial scintigraphy in asymptomatic diabetic males. Circulation, 1981, 63, 54-64.
7. Koistinen MJ. Prevalence of asymptomatic myocardial ischaemia in diabetic subjects. B Med J, 1990, 301, 92-5.
8. Naka M, Hiramatsu K, Aizawa T, et al. Silent myocardial ischemia in patients with non-insulin-dependent diabetes mellitus as judged by treadmill exercise testing and coronary angiography. Am Heart J, 1992, 123, 46-53.
9. Sukhija R, Dhanwal D, Gambhir DS, Dewan R. Silent myocardial ischaemia in patients with type 2 diabetes mellitus and its relation with autonomic dysfunction. Indian Heart J, 2000, 52, 540-6.
10. Conlon PJ, Krucoff MW, Minda S, Schumm D, Schwab SJ. Incidence and long-term significance of transient ST segment deviation in hemodialysis patients. Clin Nephrol, 1998, 49, 236-9.
11. Boon D, Pick JJ, van Montfrans GA. Silent ischaemia and hypertension. J Hypertens, 2000, 18, 1355-64.
12. Deedwania PC. Silent myocardial ischaemia in the elderly. Drugs Aging, 2000, 16, 381-9.
13. Gazzaruso C, Garzaniti A, Giordanetti S, et al. Assessment of asymptomatic coronary artery disease in apparently uncomplicated type 2 diabetic patients: A role for lipoprotein(a) and apolipoprotein(a) polymorphism. Diabetes Care, 2002, 25, 1418-24.
14. Prevalence of unrecognized silent myocardial ischemia and its association with atherosclerotic risk factors in noninsulin-dependent diabetes mellitus. Milan study on atherosclerosis and diabetes (MISAD) group. Am J Cardiol, 1997, 79, 134-9.
15. Rutter MK, McComb JM, Brady S, Marshall SM. Silent myocardial ischemia and microalbuminuria in asymptomatic subjects with non-insulin-dependent diabetes mellitus. Am J Cardiol, 1999, 83, 27-31.
16. Nesto RW, Watson FS, Kowalchuk GJ, et al. Silent myocardial ischemia and infarction in diabetics with peripheral vascular disease: Assessment by dipyridamole thallium-201 scintigraphy. Am Heart J, 1990, 120, 1073-7.
17. Cosson E, Guimfack M, Paries J, Paycha F, Attali JR, Valensi P. Are silent coronary stenoses predictable in diabetic patients and predictive of cardiovascular events? Diabetes Metab, 2003, 29, 470-6.
18. Valensi P, Sachs RN, Lormeau B, et al. Silent myocardial ischaemia and left ventricle hypertrophy in diabetic patients. Diabetes Metab, 1997, 23, 409-16.
19. Penfornis A, Zimmermann C, Boumal D, et al. Use of dobutamine stress echocardiography in detecting silent myocardial ischaemia in asymptomatic diabetic patients: A comparison with thallium scintigraphy and exercise testing. Diabet Med, 2001, 18, 900-5.
20. Cosson E, Guimfack M, Paries J, Paycha F, Attali JR, Valensi P. Prognosis for coronary stenoses in patients with diabetes and silent myocardial ischemia. Diabetes Care, 2003, 26, 1313-4.
21. Rutter MK, Wahid ST, McComb JM, Marshall SM. Significance of silent ischemia and microalbuminuria in predicting coronary events in asymptomatic patients with type 2 diabetes. J Am Coll Cardiol, 2002, 40, 56-61.
22. Vanzetto G, Halimi S, Hammoud T, et al. Prediction of cardiovascular events in clinically selected high-risk NIDDM patients. Prognostic value of exercise stress test and thallium-201 single-photon emission computed tomography. Diabetes Care, 1999, 22, 19-26.
23. Cosson E, Paycha F, Paries J, et al. Detecting silent coronary stenoses and stratifying cardiac risk in patients with diabetes: ECG stress test or exercise myocardial scintigraphy? Diabet Med, 2004, 21, 342-8.
24. Faglia E, Favales F, Calia P, et al. Cardiac events in 735 type 2 diabetic patients who underwent screening for unknown asymptomatic coronary heart disease: 5-year follow-up report from the Milan study on atherosclerosis and diabetes (MISAD). Diabetes Care, 2002, 25, 2032-6.
25. Torremocha F, Hadjadj S, Carrie F, Rosenberg T, Herpin D, Marechaud R. Prediction of major coronary events by coronary risk profile and silent myocardial ischaemia: Prospective follow-up study of primary prevention in 72 diabetic patients. Diabetes Metab, 2001, 27, 49-57.
26. Koistinen MJ, Huikuri HV, Pirttiaho H, Linnaluoto MK, Takkunen JT. Evaluation of exercise electrocardiography and thallium tomographic imaging in detecting asymptomatic coronary artery disease in diabetic patients. B Heart J, 1990, 63, 7-11.
27. Valensi P, Sachs RN, Harfouche B, et al. Predictive value of cardiac autonomic neuropathy in diabetic patients with or without silent myocardial ischemia. Diabetes Care, 2001, 24, 339-43.
28. Puel J, Valensi P, Vanzetto G, et al. Identification of myocardial ischemia in the diabetic patient. Joint ALFEDIAM and SFC recommandations.
29. Consensus development conference on the diagnosis of coronary heart disease in people with diabetes: 10-11 February 1998, Miami, Florida. American Diabetes Association. Diabetes Care, 1998, 21, 1551-9.
30. Davies RF, Goldberg AD, Forman S, et al. Asymptomatic cardiac ischemia pilot (acip) study two-year follow-up: Outcomes of patients randomized to initial strategies of medical therapy versus revascularization. Circulation, 1997, 95, 2037-43.
31. Lincoff AM. Important triad in cardiovascular medicine: Diabetes, coronary intervention, and platelet glycoprotein IIb/IIIa receptor blockade. Circulation, 2003, 107, 1556-9.
32. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med, 2003, 349, 1315-23.
33. Davies RF, Habibi H, Klinke WP, et al. Effect of amlodipine, atenolol and their combination on myocardial ischemia during treadmill exercise and ambulatory monitoring. Canadian amlodipine/atenolol in silent ischemia study (CASIS) investigators. J Am Coll Cardiol, 1995, 25, 619-25.
34. Koshiyama H. The impact of statin treatment on diabetic patients. Curr Opin Investig Drugs, 2003, 4, 395-400.
35. MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet, 2002, 360, 7-22.
36. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med, 2003, 348, 383-93.
37. Wackers F, Young L, Chyun D, Davey J, Inzucchi S, the DIAD investigators. Predictors of silent myocardial ischemia in patients with type 2 diabetes mellitus: Results from the diad study [abstract]. IDF abstact book, 2003, A63.
38. Hu FB, Stampfer MJ, Solomon CG, et al. The impact of diabetes mellitus on mortality from all causes and coronary heart disease in women: 20 years of follow-up. Arch Intern Med, 2001, 161, 1717-23.
39. Cho E, Rimm EB, Stampfer MJ, Willett WC, Hu FB. The impact of diabetes mellitus and prior myocardial infarction on mortality from all causes and from coronary heart disease in men. J Am Coll Cardiol, 2002, 40, 954-60.
40. Larsen J, Brekke M, Sandvik L, Arnesen H, Hanssen KF, Dahl-Jorgensen K. Silent coronary atheromatosis in type 1 diabetic patients and its relation to long-term glycemic control. Diabetes, 2002, 51, 2637-41.
41. Earle KA, Mishra M, Morocutti A, et al. Microalbuminuria as a marker of silent myocardial ischaemia in IDDM patients. Diabetologia, 1996, 39, 854-6.
42. Inoguchi T, Yamashita T, Umeda F, et al. High incidence of silent myocardial ischemia in elderly patients with non insulin-dependent diabetes mellitus. Diabetes Res Clin Pract, 2000, 47, 37-44.
43. Janand-Delenne B, Savin B, Habib G, Bory M, Vague P, Lassmann-Vague V. Silent myocardial ischemia in patients with diabetes: Who to screen. Diabetes Care, 1999, 22, 1396-400.
44. Valensi P, Paries J, Torremocha F, et al. Predictive value of silent myocardial ischemia in diabetic patients. Influence of age [abstract]. Diabetologia, 2000, 43 (suppl.1), A 61.
45. Airaksinen KE. Silent coronary artery disease in diabetes - a feature of autonomic neuropathy or accelerated atherosclerosis? Diabetologia, 2001, 44, 259-66.
46. Vinik AI, Maser RE, Mitchell BD, Freeman R. Diabetic autonomic neuropathy. Diabetes Care, 2003, 26, 1553-79.
47. Cohn JN, Hoke L, Whitwam W, et al. Screening for early detection of cardiovascular disease in asymptomatic individuals. Am Heart J, 2003, 146, 679-85.
48. Boucher B, Cerisier A, Bouchou K, et al. Ischémie myocardique silencieuse chez le diabétique de type 2. Valeur prédictive de l'épaisseur intima-media. Presse Med, 2002, 31, 218-22.
49. Hoff JA, Quinn L, Sevrukov A, et al. The prevalence of coronary artery calcium among diabetic individuals without known coronary artery disease. J Am Coll Cardiol, 2003, 41, 1008-12.
50. Shaw LJ, Raggi P, Schisterman E, Berman DS, Callister TQ. Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology, 2003, 228, 826-33.
51. Bacci S, Villella M, Villella A, et al. Screening for silent myocardial ischaemia in type 2 diabetic patients with additional atherogenic risk factors: Applicability and accuracy of the exercise stress test. Eur J Endocrinol, 2002, 147, 649-54.
52. Paillole C, Passa P, Paycha F, et al. Non-invasive identification of severe coronary artery disease in patients with long-standing diabetes mellitus. Eur J Med, 1992, 1, 464-8.
53. DePuey EG, Garcia EV. Optimal specificity of thallium-201 SPECT through recognition of imaging artifacts. J Nucl Med, 1989, 30, 441-9.
54. Nitenberg A, Valensi P, Sachs R, Dali M, Aptecar E, Attali JR. Impairment of coronary vascular reserve and Ach-induced coronary vasodilation in diabetic patients with angiographically normal coronary arteries and normal left ventricular systolic function. Diabetes, 1993, 42, 1017-25.
55. Nitenberg A, Paycha F, Ledoux S, Sachs R, Attali JR, Valensi P. Coronary artery responses to physiological stimuli are improved by deferoxamine but not by L-arginine in non-insulin-dependent diabetic patients with angiographically normal coronary arteries and no other risk factors. Circulation, 1998, 97, 736-43.
56. Nitenberg A, Ledoux S, Valensi P, Sachs R, Attali JR, Antony I. Impairment of coronary microvascular dilation in response to cold pressor - induced sympathetic stimulation in type 2 diabetic patients with abnormal stress thallium imaging. Diabetes, 2001, 50, 1180-5.
57. Nitenberg A, Valensi P, Sachs R, Cosson E, Attali JR, Antony I. Prognostic value of epicardial coronary artery constriction to the cold pressor test in type 2 diabetic patients with angiographically normal coronary arteries and no other major coronary risk factors. Diabetes Care, 2004, 27, 208-15.
58. Schachinger V, Britten MB, Zeiher AM. Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation, 2000, 101, 1899-906.
59. Suwaidi JA, Hamasaki S, Higano ST, Nishimura RA, Holmes DR, Jr., Lerman A. Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction. Circulation, 2000, 101, 948-54.
60. Cosson E, Paycha F, Tellier P, et al. Lower-limb vascularization in diabetic patients. Assessment by thallium-201 scanning coupled with exercise myocardial scintigraphy. Diabetes Care, 2001, 24, 870-4.
61. Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med, 1999, 340, 115-26.
62. Albertini JP, Valensi P, Lormeau B, Vaysse J, Attali JR, Gattegno L. Soluble L-selectin level is a marker for coronary artery disease in type 2 diabetic patients. Diabetes Care, 1999, 22, 2044-8.
63. Albertini JP, Cosson E, Gattegno L, Paries J, Attali JR, Valensi P. Searching new biological markers for myocardial ischemia in diabetic patients [abstract]. Diabetes Metab, 2003, 29, 2582.
64. Piot C, Fontbonne A, Sultan A, et al. Inflammatory parameters are independent predictors of severe epicardial coronary stenosis in asymptomatic diabetic patients with silent myocardial ischemia. Diabetes Care, 2003, 26, 545-6.
65. Guevara NV, Chen KH, Chan L. Apoptosis in atherosclerosis: Pathological and pharmacological implications. Pharmacol Res, 2001, 44, 59-71.
66. Cosson E, Bringuier AF, Pariès J, et al. Fas/Fas-Ligand pathway is impaired in patients with type 2 diabetes. Influence of hypertension and insulin resistance. Diabetes Metab, 2005, 31, 47-54.
67. Gazzaruso C, Garzaniti A, Giordanetti S, Falcone C, Fratino P. Silent coronary artery disease in type 2 diabetes mellitus: The role of lipoprotein(a), homocysteine and apo(a) polymorphism. Cardiovasc Diabetol, 2002, 1, 5.
68. Cosson E, Valensi P, Paycha F, et al. Can we improve the cost/effectiveness ratio in the assessment of silent myocardial ischemia and coronary stenoses on angiography in diabetic patients? [abstract]. Diabetes, 50, 2001, 2, 606.